Class / Patent application number | Description | Number of patent applications / Date published |
536053000 | Oxygen double bonded and nitrogen bonded directly to the same carbon | 57 |
20080214802 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia - Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein. | 09-04-2008 |
20090076257 | Ester Derivatives of Hyaluronic Acid for the Preparation of Hydrogel Materials by Photocuring - The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs. | 03-19-2009 |
20090318678 | Stable C-Glycoside Sugar and C-Glycoconjugate Mimetics, Method for preparing same and uses Thereof in Particular in Cosmetics and Drugs - The invention concerns a C-glycoside compound of formula (I); wherein: n is equal to 1 or 2; Y represents H or halogen; X is an alkyl chain bearing at least one amino, amide, acid, ester, carbonyl, alcohol, aryl function or a carbonyl, ester amide, amino, alcohol group; the R's, identical or different, represent a OH or OR′ group where R′ is an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl, tertiobutyldiphenylsilyl group or one or more sugars; R1 represents OR′, NR″R″′, N3, or a phthalamide with R″ and R″′, identical or different, represent H or an alkyl, aryl, benzyl, benzoyl, acetyl, alkoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl group; R2 represents H or halogen or a OH, OR, NR″R″′ or N3 group, as well as derivatives thereof in physiologically or pharmaceutically acceptable base, mineral or organic acid-addition salt, hydrate or solvate form. The invention is useful for preparing C-glycoside compounds or C-glycoconjugates applicable in particular in cosmetology, medical imagery, immunology for treating cancer, diabetes, hypertension. | 12-24-2009 |
20090326215 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE - Glucopyranosyl-substituted benzene derivatives of general formula I | 12-31-2009 |
20100093993 | TREHALOSE COMPOUND, PROCESS FOR PRODUCTION OF THE COMPOUND, AND IMMUNO-STIMULATIVE AGENT COMPRISING THE COMPOUND - An object of the present invention is to provide a novel trehalose compound that exhibits excellent immunostimulating activity and that can be supplied in a large quantity in an industrial scale, and a method for producing the trehalose compound, wherein the trehalose compound of the present invention exhibits excellent immunostimulating activity, and is represented by general formula (1) below: | 04-15-2010 |
20100099861 | SEPARATING AGENT FOR OPTICAL ISOMER - Provided is a complex obtained by reacting a polymer compound derivative obtained by modifying part of hydroxy groups or amino groups of a polymer compound having the hydroxy groups or amino groups with a compound represented by the following general formula (I) with one or more kinds of compounds represented by the following general formulae (II) to (V): (I) A-X—Si(Y) | 04-22-2010 |
20100197904 | CATIONIZED HYALURONIC ACID AND/OR SALT THEREOF, METHOD OF PRODUCING THE SAME, HAIR MODIFYING AGENT, CUTICLE REPAIRING AGENT, SKIN MODIFYING AGENT, AND COSMETIC PREPARATION EACH USING THE SAME - A cationized hyaluronic acid and/or a salt thereof includes a quaternary ammonium group-containing group, and has a degree of cationization of 0.15 to 0.6. | 08-05-2010 |
20100292459 | DERIVATIVES OF ACID POLYSACCHARIDES - Acid polysaccharides characterised by the concomitant presence of partial esters with non-polysaccharide carboxylic acids and esters between the acid groups of the initial polysaccharide and the alcohol groups of the repetitive units, with the formation of crosslinking among the polysaccharide chains. Process for the preparation of these derivatives comprising the reaction, in homogenous phase in the protic, polar solvent formamide, of the salt of a monovalent inorganic cation of the selected carboxylated polysaccharide with an anhydride of an alkylcarboxylic acid in the presence of a basic catalyst containing an atom of trisubstituted nitrogen. The formamide hydrolysis leads to the formation of a formate ester. | 11-18-2010 |
20100317842 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry - The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents. | 12-16-2010 |
20110034684 | Process For Preparing Crosslinked Hyaluronic Acid Gel - A novel process which can simply prepare a crosslinked hyaluronic acid gel having a small crosslinking agent content and exhibiting excellent viscoelasticity is provided. | 02-10-2011 |
20110060138 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders - One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera. | 03-10-2011 |
20110071285 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS - The invention relates to novel amidines and quanidines, the production and use thereof and the use thereof as trypsine-type serine protease competitive inhibitors, especially thrombine and compliment proteases CIs and C1r. The invention also relates to pharmaceutical compositions which contain said compounds as active ingredients, in addition to the use of the compounds as thrombine inhibitors, anticoagulants, compliment inhibitors and anti-inflammatory agents. The novel compositions are characterised by the linkage of a serine protease inhibitor having amidine or guanidine functions with an alkyl radical having two or more hydroxyl functions, whereby said alkyl radical is derived from sugar derivates. Several sugar structural components or components derived from sugar can therefore be linked to each other. Said principle of linking sugar derivates enables oral active compounds to be obtained. | 03-24-2011 |
20110294998 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions comprising polymeric moieties covalently attached to therapeutic agents, wherein the therapeutic agent is attached to the polymeric moiety through a tether. By selecting from a variety of tether groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. | 12-01-2011 |
20110306759 | 4-ISOPROPYLPHENYL GLUCITOL COMPOUNDS AS SGLT1 INHIBITORS - The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. | 12-15-2011 |
20120004405 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT CFTR CELLULAR PROCESSING - The present invention relates to a compound which is characterized by the formula (I) or a pharmaceutically acceptable salt, solvate, hydrate thereof, wherein the ring systems A and B are independently selected from a monosaccharide, aryl (preferably phenyl), a heteroaryl or cycloalkyl (preferably cyclohexan), preferably with all substituents in equatorial configurations; R1 is independently selected from alkyl (preferably C1 to C6), a substituted or unsubstituted phenyl, preferably CH3; R2 is H, alkyl (preferably C1 to C6), a carbohydrate in a glycosidic β-linkage, preferably H; R3, R4, R5, and R6 are independently selected from H, (OH) hydroxy, alkyl preferably C1 to C6, alkoxy (preferably C1 to C6), amino, alkylamino (preferably C1 to C6), halogen, benzylamino, or benzoylamino; X is O, NH, alkylamino (NR), CO, S; and Y is O, NH, alkylamino (NR), CO, S. The present invention also relates to the compound of the invention and, optionally, a pharmaceutically acceptable carrier, for use in the treatment of (for treating) and/or preventing a disease or medical condition which is associated with mutant CFTR. | 01-05-2012 |
20120095203 | NOVEL SILANE COMPOUNDS HAVING A CYCLIC CARBON CHAIN INCLUDING AN ALKYNE FUNCTION FOR FUNCTIONALISING SOLID SUBSTRATES AND IMMOBILISING BIOLOGICAL MOLECULES ON SAID SUBSTRATES - The invention relates to a silane compound including a cycloalkyne functionality, to a method for functionalising a solid substrate, and to the solid substrate thus produced. The silane compound of the invention corresponds to the formula X-E-A-Z where X is a silyl group, E is an organic spacer group, A is a single bond or a —CONH—, —NHCO—, —OCH | 04-19-2012 |
20120123111 | N -Hydroxy-L-Arginine Derivatives for the Treatment of Diseases - The present invention relates to physically-chemically and pharmacokinetically enhanced N | 05-17-2012 |
20120130063 | METHOD OF PRODUCING A PURIFIED HYALURONIC ACID TYPE - Provided a method of producing a purified hyaluronic acid type which comprises adding a water-soluble organic medium to a solution which comprises a hyaluronic acid type having an average molecular weight of 400 to 100,000 and has a pH of 3 or less to obtain a suspension, and adjusting a pH of the suspension in a range of 3.5 to 8 to precipitate a purified hyaluronic acid type. | 05-24-2012 |
20120184728 | Compound Amycolose Derivative, Method for Producing the Same, and Use of the Same - A compound having a structure expressed by the following General Formula (1) or a salt thereof | 07-19-2012 |
20120220763 | Methods for Extraction and Purification of Gangliosides - Methods for purification and extraction of GM1 ganglioside from cells derived from sheep afflicted with GM1 gangliosidosis or from cells derived from human patients with GM1 gangliosidosis as stable and renewable sources of GM1. | 08-30-2012 |
20120232261 | METHOD FOR MANUFACTURING LOW MOLECULAR WEIGHT HYALURONIC ACID - The present invention relates to a method for preparing low molecular weight hyaluronic acid from high molecular weight hyaluronic acid which is produced by | 09-13-2012 |
20120264927 | METHODS FOR LABELING GLYCANS - Methods for labeling glycans that include a step of freeze-drying a labeled glycan preparation. The labeled glycan preparation is maintained in a substantially frozen state for the duration of the freeze-drying process. | 10-18-2012 |
20120264928 | THERAPEUTIC PHARMACEUTICAL AGENT FOR DISEASES ASSOCIATED WITH DECREASE IN FUNCTION OF GNE PROTEIN, FOOD COMPOSITION, AND FOOD ADDITIVE - Disclosed are a therapeutic pharmaceutical agent for diseases associated with the decrease in the function of GNE protein, a food composition, and a food additive. The therapeutic pharmaceutical agent is characterized by comprising a compound capable of increasing the quantity of N-acetylneuraminic acid in cells. Examples of the compound to be contained in the therapeutic pharmaceutical agent include N-acetylneuraminic acid, an intermediate produced downstream from N-acetylmannosamine in an N-acetylneuraminic acid biosynthesis pathway, an N-acetylneuraminic acid derivative, an N-acetylmannosamine derivative, an N-acetylneuraminic acid-containing compound, an N-acetylneuraminic acid derivative-containing compound, an N-acetylmannosamine-containing compound, an N-acetylmannosamine derivative-containing compound, an inhibitor of a degrading enzyme for N-acetylneuraminic acid, an inhibitor of a degrading enzyme for N-acetylmannosamine, an inhibitor of a degrading enzyme for the intermediate, and others. | 10-18-2012 |
20120283428 | HYALURONIC ACID DERIVATIVE EFFECTIVE AGAINST ATOPIC DERMATITIS, AND METHOD FOR MANUFACTURING SAME - Disclosed are a hyaluronic acid derivative effective against atopic dermatitis, and a method for manufacturing same. The method for manufacturing the hyaluronic acid derivative of the present invention comprises: a first step of chlorinating ascorbic acid; a second step of producing a tetrabutylamonium hydroxide (TBA) salt of hyaluronic acid; and a third step of conjugating the ascorbic acid chlorinated in the first step and the TBA salt of hyaluronic acid produced in the second step. The hyaluronic acid derivative can effectively decrease the substances causing skin lesions, can contribute toward the remission of atopic disease, and is effective in skin renewal. | 11-08-2012 |
20120283429 | Biodegradable Hyaluronic Acid Derivative - The description provides a biodegradable hyaluronic acid derivative including at least one modified hyaluronic acid repeating unit represented by the formula (HA)-[O(C═O)NH-M]p, wherein HA is a unit including N-acetyl-D-glucosamine and D-glucuronic acid, M is a modifying moiety containing a C | 11-08-2012 |
20120316329 | MODIFIED HYALURONIC ACID AND/OR A SALT THEREOF, METHOD FOR PRODUCING THE SAME, AND COSMETIC PREPARATION COMPRISING THE SAME - A modified hyaluronic acid and/or a salt thereof comprises a glycerin skeleton-containing group shown by the following general formula (1), | 12-13-2012 |
20130023658 | TUNABLY CROSSLINKED POLYSACCHARIDE COMPOSITIONS - The present invention generally relates to novel biocompatible crosslinked polysaccharide gel compositions, methods of their manufacture and use, and the novel crosslinkers used to make them. In one aspect of the invention, a novel polyethylene glycol crosslinking agent is described for crosslinking hyaluronic acid. In another aspect of the invention, novel crosslinking agents comprising more than two functional groups are described. These multifunctional crosslinking agents can be used on their own to crosslink hyaluronic acid, or they may be combined with bifunctional crosslinking agents in varying ratios to make hyaluronic acid of tunable mechanical strength and hardness. The present invention also discloses novel hyaluronic acid compositions that have been coated with polyethylene glycol and methods of their use. | 01-24-2013 |
20130066064 | NOVEL PROCESS - A single-phase LPS extraction composition comprising water, an alcohol and a further organic solvent, where the amount of water is between about 0.8 to 1.2% (v/v). | 03-14-2013 |
20130079507 | SEPARATING AGENT FOR OPTICAL ISOMERS - The present invention provides a separating agent for optical isomers that contains a cellulose derivative or amylose derivative that has an excellent enantioselective recognition ability. The present invention comprises a separating agent for optical isomers that uses a polysaccharide derivative provided by replacing all or a portion of the hydrogen atoms on the hydroxyl groups present in a polysaccharide with two specific atomic groups that act on optical isomers targeted for separation in an optical resolution, wherein the sum of the average introduction ratios of specific terminal substituents in these atomic groups is greater than 3.0 per monosaccharide unit. | 03-28-2013 |
20130096294 | SIALIC ACID DERIVATIVES - An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids. | 04-18-2013 |
20130123487 | CONTROLLED RELEASE FROM SOLID SUPPORTS - The invention relates to solid supports useful in medical applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the solid support through a linkage that releases the drug or a prodrug through controlled beta elimination. | 05-16-2013 |
20130144050 | CRYSTAL FORM OF 4-ISOPROPYLPHENYL GLUCITOL COMPOUND AND PROCESS FOR PRODUCTION THEREOF - A highly stable crystal of (1S)-1,5-anhydro-1-[5-(4-{(1E)-4-[(1-{[2-(dimethylamino)ethyl]amino}-2-methyl-1-oxopropan-2-yl)amino]-3,3-dimethyl-4-oxobut-1-en-1-yl}benzyl)-2-methoxy-4-(propan-2-yl)phenyl]-D-glucitol, and a process for producing the crystal are provided. Specifically, an ethanolate having the following physical properties, and a plurality of other crystal forms transformed from the ethanolate are provided:
| 06-06-2013 |
20130165645 | 4-ISOPROPYL-6-METHOXYPHENYL GLUCITOL COMPOUND - A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided: | 06-27-2013 |
20130178613 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 07-11-2013 |
20130203979 | USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES - This invention provides compounds represented by the structure of the general formula (A): | 08-08-2013 |
20130203980 | EXOPOLYSACCHARIDE OF SHIGELLA SONNEI BACTERIA, METHOD FOR PRODUCING SAME, VACCINE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - For the first time, an O-specific polysaccharide antigen that is a | 08-08-2013 |
20130245247 | MODIFIED POLYURONIC ACIDS AND SALTS THEREOF - The present invention relates to a modified polyuronic acid represented by the following general formula (1) or a salt thereof which is excellent in surface activity: wherein R | 09-19-2013 |
20130303748 | METHOD FOR MAKING ALDEHYDE-FUNCTIONALIZED POLYSACCHARIDES - A method for making aldehyde-functionalized polysaccharides having pendant aldehyde groups is described. The method involves the hydroformylation of an alkene-functionalized polysaccharide. The resulting aldehyde-functionalized polysaccharides are useful for forming hydrogel tissue adhesives and sealants for medical applications. | 11-14-2013 |
20140011990 | CROSS-LINKING OF LOW-MOLECULAR WEIGHT AND HIGH-MOLECULAR WEIGHT POLYSACCHARIDES, PREPARATION OF INJECTABLE MONOPHASE HYDROGELS, POLYSACCHARIDES AND HYDROGELS OBTAINED - A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof. Crosslinked polymers and injectable monophase hydrogels respectively obtainable by each of said processes. | 01-09-2014 |
20140046051 | N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE - A compound of the formula (1) wherein R | 02-13-2014 |
20140073772 | Biotechnological Production of Chondroitin - Chondroitin is produced by culturing a recombinant microorganism which is obtained by inactivation of a gene encoding an enzyme responsible for addition of fructose residues to the linear chondroitin polysaccharide in a microorganism producing a fructosylated derivative of chondroitin. | 03-13-2014 |
20140163217 | PROCESS FOR THE ESTERIFICATION OF HYALURONIC ACID WITH HYDROPHOBIC ORGANIC COMPOUNDS - The invention relates to a process for providing esters of hyaluronic acid, hyaluronic acid salts or hyaluronic acid derivatives with hydrophobic organic compounds. The process includes the steps of (i) micronizing the hyaluronic acid, salt or derivative thereof at reduced temperature, (ii) reacting the hydrophobic compound with a micronized hyaluronic acid obtained in (i) in a suitable solvent; and (iii) filtrating or dialyzing reaction mixture obtained in (ii) to obtain the desired ester. Also encompassed by the present invention are the esters obtained by such a method and compositions containing them as well as the use thereof for treating and/or preventing cartilage damage and inflammation. | 06-12-2014 |
20140296505 | COMPOSITIONS AND METHODS FOR BACTERIAL PRODUCTION OF CHONDROITIN - The invention relates to the field of recombinant DNA technology for the production of chondroitin, including the production of chondroitin sulfate via a combination of recombinant bacterial fermentation and post-fermentation sulfation. | 10-02-2014 |
20140303363 | Preparation and Use of Isolactosamine and Intermediates therefor - The invention relates to providing isolactosamine (Galβ1-3GlcNH | 10-09-2014 |
20140343269 | METHOD OF PURIFYING LOW MOLECULAR WEIGHT HYALURONIC ACID OR CATIONIZED HYALURONIC ACID VIA PRECIPITATION FROM AQUEOUS SOLUTION BY ADDITION OF ALCOHOL OR ACETONE FOLLOWED BY pH ADJUSTMENT - Provided a method of producing a purified hyaluronic acid type which comprises adding a water-soluble organic medium to a solution which comprises a hyaluronic acid type having an average molecular weight of 400 to 100,000 and has a pH of 3 or less to obtain a suspension, and adjusting a pH of the suspension in a range of 3.5 to 8 to precipitate a purified hyaluronic acid type. | 11-20-2014 |
20140378678 | Compositions and Methods for Recombinant Synthesis of High Molecular Weight Hyaluronic Acid - Provided is a novel hyaluronan synthase (HAS2), isolated nucleic acids encoding it, and expression vectors which express the novel HAS2. Also provided are cell cultures which contain cells which harbor the expression vectors, methods of using the cell cultures to produce high molecular weight hyaluronic acid, and cell culture media that contains the high molecular weight hyaluronic acid. | 12-25-2014 |
20150025233 | USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES - This invention provides compounds represented by the structure of the general formula (A): | 01-22-2015 |
20150038693 | SIALIC ACID ANALOGS - The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies. | 02-05-2015 |
20150065701 | INJECTABLE MONOPHASE HYDROGELS - An injectable monophase hydrogel is provided and is made of a reaction mixture of a high molecular weight hyaluronic acid and a low molecular weight hyaluronic acid. | 03-05-2015 |
20150119567 | LIPID-POLYMER CONJUGATES, THEIR PREPARATION AND USES THEREOF - This invention provides low molecular weight lipid-GAG and phospholipids-GAG conjugates and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. | 04-30-2015 |
20150126727 | NOVEL PROCESS - The present invention provides a method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells comprising the step: extracting LPS from the cell culture in a composition (LPS extraction composition) comprising water, an alcohol and a further organic solvent. | 05-07-2015 |
20150343018 | NOD2-DEPENDENT PATHWAY OF CYTOPROTECTION OF STEM CELLS - The present invention is directed to an agonist of NOD2 for use in therapy for increasing the autonomous capacity of survival of vertebrate adult stem cells, without loss of their capacity to multiply and differentiate, and preferably the capacity of survival of intestinal stem cells, especially in response to a stress. The invention also concerns the use of an agonist of Nod2 for increasing in vitro or ex vivo the autonomous capacity of survival, without loss of multiplication and differentiation capacity of mammalian adult stem cell. The invention also discloses different media and support for mammalian adult stem cells. The invention also concerns an in vitro screening process for identifying molecules capable increasing, in response to a stress, the autonomous capacity of survival, without loss of multiplication and differentiation capacity of mammalian adult stem cells. | 12-03-2015 |
20160075729 | SYNTHESIS OF SIALYLATED/FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES - An achemo-enzymatic synthesis of oligosaccharides of formula 1 is presented wherein R is selected from —OH, —N3 and —OR6 wherein R6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally substituted by one or more methyl, 2-trimethylsilyl-ethyl, —(CH2)n—NH2 and —(CH2)n—N3 wherein integer n is to 10, preferably 2 or 3, R is selected from sialyl moiety, —SO3H and —CH(R)—COOH wherein R is selected from H, alkyl and benzyl, R2 is selected from H and fucosyl, R3 is selected from H and sialyl, R4 is selected from H and fucosyl, provided that at least one of R3 and R4 is H, and A is a divalent carbohydrate linker, having important biological activities and significant commercial value for the pharmaceutical and food industry. | 03-17-2016 |
20160096905 | Reduction of Endotoxin in Polysialic Acids - The present invention relates to process for reducing the endotoxin content of a sample of fermentation broth containing polysialic acid and endotoxin comprising the sequential steps: (i) adding to the sample a base having a pKa of at least 12 to form a basic solution having a pH of at least 12, incubating the solution for a pre-determined time at a pre-determined temperature; and (ii) recovery of PSA, suitably by (iii) passing the sample through an anion-exchange column whereby polysialic acid is absorbed on the ion exchange resin; (iv) washing the column with one washing buffer, whereby polysialic acid remains absorbed on the ion exchange resin; and (v) eluting the polysialic acid from the column using an elution buffer to provide a product solution of polysialic acid having reduced endotoxin content. | 04-07-2016 |
20160108139 | BIOTECHNOLOGICAL SULPHATED CHONDROITIN SULPHATE AT POSITION 4 OR 6 ON THE SAME POLYSACCHARIDE CHAIN, AND PROCESS FOR THE PREPARATION THEREOF - The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly from | 04-21-2016 |
20160145357 | METHOD FOR MANUFACTURING A SHAPED CROSSLINKED HYALURONIC ACID PRODUCT - A method for manufacturing a shaped cross-linked hyaluronic acid product, the method including the step of subjecting a non-cross-linked precipitated hyaluronic acid substrate in a desired shape to a single cross-linking reaction in a liquid medium having a pH of 11.5 or higher and including one or more polyfunctional cross-linking agent(s) and an amount of one or more organic solvent(s) giving precipitating conditions for hyaluronic acid, under suitable conditions to obtain a precipitated, shaped cross-linked hyaluronic acid product having a degree of modification of 1-40 cross-linking agent units per 1000 disaccharide units. | 05-26-2016 |
20160151506 | GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME | 06-02-2016 |